Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma

20075,732 citationsJournal Articlebronze Open Access

Authors

Robert J. Motzer · Memorial Sloan Kettering Cancer Center

Thomas E. Hutson · Texas Oncology

Piotr Tomczak · Centrum Onkologii

M. Dror Michaelson · Massachusetts General Hospital

Ronald M. Bukowski · Cleveland Clinic

Olivier Rixe · Sorbonne Université

Stéphane Oudard ·

Abstract

Progression-free survival was longer and response rates were higher in patients with metastatic renal-cell cancer who received sunitinib than in those receiving interferon alfa (ClinicalTrials.gov numbers, NCT00098657 and NCT00083889 [ClinicalTrials.gov]).

Topics & Keywords

Renal cell carcinoma treatment Renal and related cancers Cancer Genomics and Diagnostics

Publication Details

Published in: New England Journal of Medicine

Volume 356, Issue 2, pp. 115-124

DOI: 10.1056/nejmoa065044

Field-Weighted Citation Impact: 387.41

Command Palette

Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma

Authors

Abstract

Topics & Keywords

Publication Details